A Cambridge-based biotech developing a new type of medicine built from short synthetic peptides called bicycle molecules, mainly for cancer.
Bicycle Therapeutics develops new medicines based on short synthetic peptides called bicycle molecules. These are small, tightly looped chains of amino acids designed to find and attach to disease targets. Its work focuses on cancer, and its medicines are in clinical trials to test safety and effectiveness.
It was founded in 2009. A regional business article describes its goal as new drugs for diseases with high medical need. We did not find a formal values statement on the pages we read.
The company is headquartered in Cambridge, UK, and the same article says it has about 300 people, around two-thirds in the UK and the rest in the US. That article is a few years old, so headcount may have changed.
Its chief technology officer is quoted as saying that encouraging future talent is "an obligation" and a personal passion. The company says it wants energetic, ambitious and committed scientists. These are its own claims.
Bicycle has worked with the University of Bath since 2017, and with other universities including Cambridge, to host undergraduate students who join project teams and work alongside key staff. Some later join Bicycle full time. We did not find a graduate scheme, apprenticeships or formal internship programme, so check its careers page and university placement offices.
Website: www.bicycletherapeutics.com
PURPOSE helps school and university students explore 62 sectors and over 1,000 entry-level careers in the UK, then connects them directly with employers.
Explore PURPOSE